Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351817 | 0.91 | HDAC1 (0.40) | MEN1KMT2AHDAC1HDAC8HDAC6 | |
| SCHEMBL1689600 | 0.90 | HDAC1 (0.51) | NOTUMMEN1KMT2AHDAC1HDAC8 | |
| SCHEMBL1689637 | 0.83 | NOTUM (0.68) | NOTUMMEN1KMT2AHDAC1HDAC8 | |
| SCHEMBL13722978 | 0.82 | MEN1 (0.36) | NOTUMMEN1KMT2APOLBJAK2 | |
| SCHEMBL1689732 | 0.80 | NOTUM (0.51) | NOTUMTACR3PROKR1 | |
| SCHEMBL6179731 | 0.78 | MEN1 (0.61) | MEN1KMT2APOLBPROKR1 | |
| SCHEMBL13968939 | 0.77 | KCNA5 (0.50) | NOTUMMEN1KMT2A | |
| SCHEMBL2910875 | 0.77 | NOTUM (0.43) | NOTUMMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL10257965 | 0.77 | NOTUM (0.43) | NOTUMMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL2910873 | 0.77 | NOTUM (0.43) | NOTUMMEN1KMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2531506-B1 | Spiroindoline compounds for use as anthelminthics | INTERVET INT BV (NL) | 2014-05-14 | — | — | EP | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011095581-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | INTERVET INTERNATIONAL B.V. (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | NOTUM 1354/4885MEN1 2072/4885KMT2A 1550/4885 |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | NOTUM 1354/4885MEN1 2072/4885KMT2A 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.